



# 3

**PATENT**

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:  
Dmitry Gabrilovich et al.

Serial No.: 09/526,320

Filed: March 15, 2000

For: DENDRITIC CELLS TRANSDUCED  
WITH A WILD-TYPE SELFGENE  
ELICIT POTENT ANTITUMOR IMMUNE  
RESPONSES

Group Art Unit: 1636

Examiner: Unknown

Atty. Dkt. No.: INRP:074/SLH

ELECTION UNDER 37 C.F.R. §§ 3.71 AND 3.73  
AND POWER OF ATTORNEY

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

The undersigned, being an Assignee of record of an interest in the above-identified application by virtue of an assignment recorded in the United States Patent and Trademark Office as set forth below, hereby elects, under 37 C.F.R. § 3.71, to prosecute the application to the exclusion of the inventors.

The Assignee hereby revokes any previous Powers of Attorney and appoints:

Louis T. Pirkey, Reg. No. 22,393; Richard J. Groos, Reg. No. 32,231; David L. Parker, Reg. No. 32,165; William G. Barber, Reg. No. 33,154; David D. Bahler, Reg. No. 30,932; Stephen D. Dellett, Reg. No. 32,564; Michael S. Metteauer, Reg. No. 34,875; Mark B. Wilson, Reg. No. 37,259; Steven L. Highlander, Reg. No. 37,642; Erik R. Nordstrom, Reg. No. 39,792; Teresa J. Bowles, Reg. No. 40,526; Stephen P. Meleen, Reg. No. 40,724; Richard A. Nakashima, Reg. No. 42,023; Robert E. Hanson, Reg. No. 42,628; Nicole Stafford, Reg. No. 43,929; Michael C. Barrett, Reg. No. 44,523; Mark T. Garrett, Reg. No. 44,699; Jonathan Hurt, Reg. No. 44,790; Gina N. Shishima, Reg. No. 45,104; Debra L. Dennett, Reg. No. 46,370; and Stephen M. Hash, Reg. No. 45,490;

each an attorney or agent of the firm of FULBRIGHT & JAWORSKI L.L.P., as its attorney or agent for so long as they remain with such firm, with full power of substitution and revocation,

SEP 25 2000

to prosecute the application, to make alterations and amendments therein, to transact all business in the Patent and Trademark Office in connection therewith, and to receive any Letters Patent, and for one year after issuance of such Letters Patent to file any request for a certificate of correction that may be deemed appropriate.

Pursuant to 37 C.F.R. § 3.73, the undersigned has reviewed the evidentiary documents, specifically the Assignment to VANDERBILT UNIVERSITY, referenced below, and certifies that to the best of my knowledge and belief, title remains in the name of the Assignee.

Please direct all communications as follows:

Steven L. Highlander, Esq.  
FULBRIGHT & JAWORSKI, L.L.P.  
600 Congress Avenue, Suite 2400  
Austin, TX 78701  
(512) 418-3000

ASSIGNEE:  
VANDERBILT UNIVERSITY


By: Janis Elsner  
Name: JANIS ELSNER  
Title: ASSOCIATE DIRECTOR

Date: 9/15/00

ASSIGNMENT:

- ☒ Concurrently filed  
☐ Previously recorded

Date: \_\_\_\_\_  
Reel: \_\_\_\_\_  
Frames: \_\_\_\_\_



#3

**PATENT**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:  
Dmitry Gabrilovich et al.

Serial No.: 09/526,320

Filed: March 15, 2000

For: DENDRITIC CELLS TRANSDUCED  
WITH A WILD-TYPE SELFGENE  
ELICIT POTENT ANTITUMOR IMMUNE  
RESPONSES

Group Art Unit: 1636

Examiner: Unknown

Atty. Dkt. No.: INRP:074/SLH

ELECTION UNDER 37 C.F.R. §§ 3.71 AND 3.73  
AND POWER OF ATTORNEY

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

The undersigned, being an Assignee of record of an interest in the above-identified application by virtue of an assignment recorded in the United States Patent and Trademark Office as set forth below, hereby elects, under 37 C.F.R. § 3.71, to prosecute the application to the exclusion of the inventors.

The Assignee hereby revokes any previous Powers of Attorney and appoints:

Louis T. Pirkey, Reg. No. 22,393; Richard J. Groos, Reg. No. 32,231; David L. Parker, Reg. No. 32,165; William G. Barber, Reg. No. 33,154; David D. Bahler, Reg. No. 30,932; Stephen D. Dellett, Reg. No. 32,564; Michael S. Metteauer, Reg. No. 34,875; Mark B. Wilson, Reg. No. 37,259; Steven L. Highlander, Reg. No. 37,642; Erik R. Nordstrom, Reg. No. 39,792; Teresa J. Bowles, Reg. No. 40,526; Stephen P. Meleen, Reg. No. 40,724; Richard A. Nakashima, Reg. No. 42,023; Robert E. Hanson, Reg. No. 42,628; Nicole Stafford, Reg. No. 43,929; Michael C. Barrett, Reg. No. 44,523; Mark T. Garrett, Reg. No. 44,699; Jonathan Hurt, Reg. No. 44,790; Gina N. Shishima, Reg. No. 45,104; Debra L. Dennett, Reg. No. 46,370; and Stephen M. Hash, Reg. No. 45,490;

each an attorney or agent of the firm of FULBRIGHT & JAWORSKI L.L.P., as its attorney or agent for so long as they remain with such firm, with full power of substitution and revocation,

SEP 25 2000


to prosecute the application, to make alterations and amendments therein, to transact all business in the Patent and Trademark Office in connection therewith, and to receive any Letters Patent, and for one year after issuance of such Letters Patent to file any request for a certificate of correction that may be deemed appropriate.

Pursuant to 37 C.F.R. § 3.73, the undersigned has reviewed the evidentiary documents, specifically the Assignment to INTROGEN THERAPEUTICS, INC., referenced below, and certifies that to the best of my knowledge and belief, title remains in the name of the Assignee.

Please direct all communications as follows:

Steven L. Highlander, Esq.  
FULBRIGHT & JAWORSKI, L.L.P.  
600 Congress Avenue, Suite 2400  
Austin, TX 78701  
(512) 418-3000

ASSIGNEE:  
INTROGEN THERAPEUTICS, INC.

By:   
Name: David L. Parker  
Title: Vice President, Intellectual Property  
Date: 8/30/00

ASSIGNMENT:

☒ Concurrently filed  
☐ Previously recorded  
Date: \_\_\_\_\_  
Reel: \_\_\_\_\_  
Frames: \_\_\_\_\_